1, Wuzhong, Jiangsu: Wu Traditional Chinese Medicine, a holding subsidiary, is currently carrying out the project of "R&D and industrialization of recombinant human endostatin injection, a national first-class biological anticancer drug", which has independent intellectual property rights and was supported by the national "863" project in 2006 for non-small cell lung cancer. 20 10 1 1, won the Jiangsu Science and Technology Achievement Award.

Fruit pulp.

2. Haixin Co., Ltd.: independently developed a national first-class new drug named "antigen sensitized human dendritic cells (APDC)", which can be used to treat rectal cancer. Haixin Biotechnology Co., Ltd. (holding 565,438+0% of the shares) cooperated with Shanghai Second Military Medical University to develop a national first-class drug, which was the first drug independently developed in China and officially approved by the State Food and Drug Administration (SFDA) for APDC of advanced colorectal cancer. The 2009 annual report shows that the third phase of clinical practice has passed the expert demonstration organized by the State Administration of Pharmaceutical Products and is under examination and approval. Through hard work, the enterprise has obtained nearly 5 million yuan from the national "major new drug creation" fund.

3. Yatai Group: Invest in the pharmaceutical industry-the company takes biological vaccines and anti-tumor drugs as the development direction of new products, and has formed a series of anti-cancer products mainly based on "Shenyi Capsule" and anti-cancer biological missiles. At the same time, new anticancer drugs such as interleukin-1 1 and ginsenoside Rg3 injection have been reserved.

4. Shuanglu Pharmaceutical Co., Ltd.: The company was selected as one of the key cultivation enterprises in "Beijing Biomedical Industry Leaping Development Project" and the first batch of "10000 Project" in Zhongguancun National Independent Innovation Demonstration Zone. The company has reserved a number of superior varieties with market potential at home and abroad in the fields of tumor treatment, anti-inflammatory and analgesic, cardiovascular and cerebrovascular diseases and liver diseases, and strives to introduce more than three antibodies and vaccine drugs. Constantly cultivate heavy varieties in the field of liver disease treatment, and strive to become an important enterprise in the field of liver disease treatment in China. The company's main products, such as recombinant human granulocyte colony stimulating factor, interleukin-1 1, asparaginase and anti-tumor products, are gradually entering the markets of Eastern Europe, Asia and South America.

5. Tetracyclic organism: The company's main products include recombinant human interleukin-2 (used for comprehensive treatment of malignant tumors such as kidney cancer and malignant melanoma), recombinant human interleukin-2 injection, recombinant human granulocyte stimulating factor injection and recombinant human erythropoietin injection, among which recombinant human interleukin-2 for injection is an industrialized genetic engineering product of the national project "Development, pilot production and clinical application of genetically engineered human interleukin -2"; Beijing Sihuan Biopharmaceutical, which still holds 55% of the shares, is the earliest enterprise engaged in the research and development and production of genetic engineering drugs and diagnostic reagents in China. Its proprietary technology includes sublingual buccal tablets such as interleukin -2 (used to treat liver cancer), interferon, EPO and G-CSF.

6. Shuanghe Pharmaceutical: The company's main business is the research and development and production of genetic engineering drugs, chemicals and biochemical drugs in the fields of tumor, cardiovascular and cerebrovascular diseases, hepatitis and organ transplantation.

7. anke biotechnology Science and Technology: The company plans to introduce anti-tumor drug S- 1 tablet project. S- 1 is a new compound antitumor drug, which is mainly used to treat advanced or metastatic gastric cancer. It is estimated that 20 12 will be put into production, with an annual production capacity of 30 million pieces.

8. Fengyuan Pharmaceutical Co., Ltd.: Fengyuan Renzhong Pharmaceutical Co., Ltd., a joint venture between the company and Renzhong Technology (the company holds 60% of the shares), ensures that the new cisplatin implant anticancer drug will be listed before the end of September 2065438+2002; The company invested heavily in research and development of new drugs for adjuvant treatment of cancer.

9. ROP shares: The company holds 98.07% of Baishixin produced by Zhejiang ROP Kangyu Pharmaceutical Co., Ltd., which is a national second-class anti-tumor drug; In the first half of 20 10, the "high-tech industrialization demonstration project of enzymatic synthesis of D- p-hydroxyphenylglycine" declared by the company was included in the national high-tech industrialization demonstration project. -"Hengdian Department"

10, Southwest Synthesis: Kang Bei Disodium Phosphate (CA4P) and its injection, which the company cooperates with Founder Medical Research Institute, are vascular targeting drugs or endothelium-destroying drugs, and its mechanism of action is that the blood supply to the tumor is rapidly interrupted, leading to the death of the tumor due to insufficient oxygen supply and nutritional hunger. It will take about 5-6 years to get the approval of this medicine. -Tai Chi Department

1 1, Taiji Group: The company owns new anticancer drug preparations with independent intellectual property rights, and strives to complete the application for clinical approval by the end of 20 10/. -"Taiji Department". Four new drugs with independent intellectual property rights have been jointly developed with scientific research institutes: new anticancer drugs, new drugs for diabetes (complications) and new drugs for cardiovascular diseases, of which two have obtained clinical approval, 1 is applying for production approval, and 90 1, 902903904 and 905 new product projects have been independently screened. Scientific and technological innovation in 2009 laid a solid foundation for building innovative enterprises.

12, Fosun Pharma: The company holds 74% of Shanghai Fuhong Hanlin Biotechnology, and is committed to the research and development and industrialization of macromolecular monoclonal antibody drugs; The monoclonal antibody drug project built by the company and Chemo Group, an international pharmaceutical company, on Shanghai Kaimao Biomedical Platform will introduce four monoclonal antibody drugs for treating tumors and similar diseases. -"Renaissance Department"

13 Haizheng Pharmaceutical Co., Ltd.: The company is a leading raw material drug manufacturer in China and one of the largest production bases of antibiotics and anti-tumor drugs in China.

14, Hengrui Pharma: The company's single enantiomer chiral drug-calcium levofolinate can be used to enhance the anti-tumor activity of 5- fluorouracil, which is mainly used to treat folic acid antagonism and symptoms related to colon cancer and kidney cancer after high-dose methotrexate treatment; The company ranks first in China in a variety of anti-tumor drugs, three of which are exclusively produced in China. The existing generic drugs oxaliplatin and docetaxel are in the growth stage, and irinotecan is also entering a period of rapid growth. The company should have apatinib mesylate, a molecular targeted anti-tumor drug.

15, Zhongxin Pharmaceutical: Hualida Bioengineering, which holds 40% of the company's shares, is the first to devote itself to the research and development and industrialization of antiviral and antitumor drugs through genetic engineering pharmaceutical technology, and has the leading product "Anfulong"-the second generation of genetically engineered interferon α-2b.

16, Hainan Haiyao: The company's main products are paclitaxel injection, which can be used to treat ovarian cancer, breast cancer, lung cancer and nasopharyngeal cancer.

17, China Resources Sanjiu: Anhui Jinchan Biochemical Co., Ltd., which holds 83.68% of the shares, mainly produces cinobufagin injection, which can be used for the treatment of advanced tumors, chronic hepatitis B and other diseases. -"China Resources Department"

18, Yuheng Pharmaceutical: The company produces gemcitabine hydrochloride, an anti-tumor drug, which is mainly used to treat pancreatic cancer and non-small cell lung cancer (at present, only Lilly, Jiangsu Haosen and Yuheng Pharmaceutical produce this drug in China).

19, Laimei Pharmaceutical Co., Ltd.: The company's core technologies include nano-drug technology for lymphatic targeted therapy, micro-nano dispersed suspension preparation technology for drugs, and aseptic raw material preparation technology.

20. Renfu Pharmaceutical Co., Ltd.: gedian Renfu Pharmaceutical Co., Ltd., holding 865,438+0.07% equity, is a research and development enterprise specializing in steroid hormone raw materials, fertility regulation drugs and anti-tumor drugs; Shenzhen Xinpeng Bioengineering, which holds 52% of the shares, is developing the internationally leading anti-cancer gene drug project TR- 1, and it is expected to obtain the first-class new drug certificate within 3-5 years.

2 1, ST Changxin: Changan International Pharmaceutical Co., Ltd., which holds 5 1% of the company's shares, has an exclusive patent on the production and operation of the latest third-generation platinum anti-tumor drug lobaplatin in China.

22. Aodong, Jilin: Yanji Pharmaceutical, the holding subsidiary of the company, owns the patent of "Preparation method of compound pancreatic ribonucleic acid for injection", which takes bovine pancreas as raw material, has the functions of anti-cancer, anti-aging and enhancing immunity, reduces the toxic and side effects of radiotherapy and chemotherapy, and makes cancer cells vacuolate and dissolve.

23. Huashen Group: The primary liver cancer drug I [13 1i] Metuximab Injection (Likatine) owned by the company is a national first-class innovative drug, and it is the first gene drug in the world to treat liver cancer with monoclonal antibodies. The company has independent intellectual property rights for the treatment of advanced liver cancer.

24. guilin sanjin: The company's research projects include cancer treatment.

25. Yabao Pharmaceutical: The company is developing new and innovative anticancer drugs.

26. Tasly: Tasly Chuangshijie (Tianjin) Biopharmaceutical, established by the company in cooperation with French Genetics, will devote itself to the transgenic technology of gene immunotherapy for cancer and infectious diseases.

27. Baiyi Pharmaceutical Co., Ltd.: The company owns Aidi injection, a traditional Chinese medicine with genetic technology, and obtains VEGI proprietary technology of polypeptide chain products through genetic engineering, which can directly activate different types of immune cells and inhibit or eliminate cancer cells.

28. Neptune Biology: The company has formed a complete product system dominated by anti-tumor products and biological products, covering cardiovascular and cerebrovascular diseases, respiratory system, digestive system, etc. 1 1 category.

29. Lansheng shares: Lansheng Guo Jian Pharmaceutical Co., Ltd. and CITIC Pacific jointly established "Shanghai CITIC Guo Jian Pharmaceutical Co., Ltd.", with Lansheng Guo Jian holding 465,438+0.69% and the company holding 0.73%. In 2008, the new biological drug "Yisaipu" (recombinant human1kloc-0/tumor necrosis factor receptor-antibody fusion protein for injection) developed by CITIC Guo Jian won the second prize of the National Science and Technology Invention Award, which is the first humanized monoclonal antibody drug in China to truly realize industrialization and marketization. .

30. Fudan Hua Fu: Production of flutamide tablets, a new drug for the treatment of prostate cancer.

The first generic drug series: 1, Hengrui Pharma: oxaliplatin, docetaxel, irinotecan;

2. Hua En Medicine: Ziprasidone, original research manufacturer Pfizer;

3. Baiyun Mountain: Futai (imitation of Tamiflu);

4. Hainan Haiyao: paclitaxel injection and cefoxitin sodium;

5. Xinlitai: Taijia (clopidogrel bisulfate);

6. Shanghai medicine: imitation of Tamiflu;

7. Haizheng Pharmaceutical: Tamiflu intermediate;

8. Tong Ren Tang: Three imitation varieties have entered the production approval process;

9. Shuanghe Pharmaceutical Co., Ltd.: On March 27th, 2009, it officially launched the company's latest research and development achievement of generic drugs-"Guan Shuang generic drug name: pivacalcium";

10, Changchun High-tech: Exenatide product is the first in China to pass the examination and approval of the US Food and Drug Administration, and it is listed as the first of the four potential drugs by international diabetes experts;

1 1, Kangzhi Pharmaceutical: Ruizhiqing (Nimesulide Granule).

Exclusive Chinese medicine series:

1, Yunnan Baiyao: Baiyao series, national top secret formula, national first-class protected variety of traditional Chinese medicine;

2. Tablet strength: Tablet strength series, national top secret formula, national first-class protected variety of traditional Chinese medicine;

3. Wohua medicine: Xinkeshu tablets, a national protected variety of traditional Chinese medicine;

4. Dong 'e Ejiao: Ejiao series, the first list of national intangible cultural heritage expansion projects;

5. essence pharmaceutical: Wang Baobao Akamaru and Ji Desheng snake slices, national traditional Chinese medicine confidential varieties;

6. Zhongheng Group: Xueshuantong Injection;

7. Qianjin Pharmaceutical: Gynecological Qianjin Tablets;

8. Zhongxin Pharmaceutical: Quick-acting Jiuxin Pill, a national-level confidential Chinese medicine variety;

9. Guangyao: Xiaoke Pill;

10, Ma Yinglong: musk hemorrhoid ointment;

1 1, Lamiophlomis rotata: Lamiophlomis rotata series;

12, Jinling Pharmaceutical: Mailuoning Injection;

13, Tasly: Compound Danshen Dripping Pills;

14, China resources Sanjiu: 999 Ganmaoling, Piyanping, Zhengtian Pill, Weitai and cinobufotalin injection, prepared by the state;

15, Jiuzhitang: Lvjiao Buxue Granule and Yiganning Granule, which are the second-class protected varieties of traditional Chinese medicine. Chidan Tuihuang Granule, a national secret recipe;

16, Tongrentang: Liuwei Dihuang Pill;

17, Taiji Group: chicken juice syrup;

18, Tongjunge: Guizhi mixture, Sijunzi mixture, deworming Xiaoshi tablets, national traditional Chinese medicine protection varieties;

19, Hainan Haiyao: Liao Feng Changweikang Granule, a national protected variety of traditional Chinese medicine;

20. Jiaying Pharmaceutical: Double Hou Fengfen;

2 1, guilin sanjin: Sanjin tablets, watermelon frost series;

22. Tibetan medicine in Zheng Qi: Zheng Qi Xiaotong ointment, a national protected variety of traditional Chinese medicine and a national secret variety;

23. Tibet pharmaceutical industry: Nuodikang series;

24. Ling Rui Pharmaceutical: Tongluo Qutong Ointment and Zhuanggu Musk Ointment;

25. Luomei Pharmaceutical: Keke Jiegu Tablet, Fish Scales, Zhupo Anshen Pill, which are protected varieties of traditional Chinese medicine;

26. Yabao Pharmaceutical: Ding Gui navel paste;

27. Kangyuan Pharmaceutical: Reduning Injection and Tongan Injection;

28. Kang: Ke Daling, the exclusive variety of national traditional Chinese medicine protection. Wuling capsule, a national protected variety of traditional Chinese medicine;

29. Jiang Zhong Pharmaceutical: Compound Caoshanhu Buccal Tablets and Jiang Zhong Brand Jianwei Xiaoshi Tablets;

30. Shanghai Furen: Yixin Tongmai Granule and Yatong Xiaoyan Ling Granule;

3 1, Sanjing Pharmaceutical: Shuanghuanglian Series;

32. Wuhan Jianmin: Long Mu Zhuanggu Granule, the first batch of national first-class Chinese medicine protection varieties;

33. Angel Pharmaceutical: Bushen Anshen Oral Liquid and Simiao Pill;

34. Hokuriku Pharmaceutical: Jiuwei Zhenxin Granule;

35. Hongri Pharmaceutical: Xuebijing Injection, a state secret formula;

36. Baiyi Pharmaceutical: Aidi injection, a state secret formula;

37. Fu Rui shares: the world's first professional drug for treating liver fibrosis-Compound Biejia Ruangan Tablet;

38. Hansen Pharmaceutical: Simotang;

39. Tai 'antang: Xiaoyan Zigypsum, Xinbao Pill and Kirin Pill;

Exclusive vaccine series: 1, Tiantan Bio: Ma Haifeng Triple Vaccine is the first in China;

2. Changchun Hi-Tech: varicella and anti-AIDS vaccine;

3. Yueyang Xingchang: Stomach disease vaccine;

4. Chongqing Beer: Hepatitis B vaccine;

5. watson biological: vaccines such as meningitis and pneumonia;

6. Li Sheng Pharmaceutical: pneumonia, chickenpox, hepatitis A and hepatitis B vaccines;

7. zhifei Biology: Meningitis, Vika;

8. Ke Hua Biology: The nucleic acid detection kit for hepatitis B virus, hepatitis C virus and human immunodeficiency virus (type ι) produced by the company (PCR- fluorescence method) obtained the new drug certificate and production approval number of the Food and Drug Administration.

European and American series: 1, Jingxin Pharmaceutical: Simvastatin API;

2. Hua En Medicine: After Gabapentin Ding Yu obtained the GMP certification of the European Union on February 2, 2009, the company obtained the new drug certificate and production approval issued by SFDA on February 5;

3. Xianghai Pharmaceutical Co., Ltd.: the only manufacturer of biphenyl diester in China and the only China company to enter the international BIT product market;

4. Modern pharmacy: anti-AIDS drugs will pass FDA certification; The largest manufacturer of lipoic acid raw materials in China, 90% of its products are exported to Japan and Europe. The only enterprise in China that has mastered the chiral resolution technology of lipoic acid can produce high-end products with low residual lipoic acid;

5. Southwest Synthesis: All products have passed GMP certification, among which 9 products are registered with the US FDA, 4 products have passed FDA certification, and 5 products have obtained European COS certificates;

6. Fosun Pharma: Artesunate tablets passed the GMP review of WHO and became the third largest direct supplier of antimalarial drugs in the world by WHO, which completely opened the road to internationalization of the company. In 2008, the export of antimalarial drugs of Artemisia annua continued to be the first;

7. Huadong Medicine: The leading product, cyclosporine, has passed the COS certification of the EU Drug Quality Management Committee, with a validity period of 5 years;

8. Haizheng Pharmaceutical: At the end of 2008, the number of COS certifications of FDA and EU reached 18 and 15 respectively, and more than 20 products were being declared;

9. Zhongxin Pharmaceutical: Xiao Su Jiuxin Pill formula is listed as a state secret formula, Shunaoxin Dropping Pill is the first Chinese medicine dripping pill preparation for treating cerebrovascular diseases, the first Chinese medicine product to enter the EU, and Huoxiang Zhengqi Soft Capsule is the first Chinese patent medicine soft capsule preparation in China;

10, Huahai Pharmaceutical Co., Ltd.: It has become the only enterprise in the three series of protease inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors required by HAART (cocktail therapy), an anti-AIDS drug in China, which has been approved by the state.

1 1, Tasly: 2010 65438+1On October 20th, the phase II clinical trial of the main product, Compound Danshen Dripping Pills (FDA), was completed. The purpose of this phase II clinical trial is to determine the curative effect and dose response of Compound Danshen Dripping Pills on American patients with chronic stable angina pectoris. 20 10 was approved by the third phase clinical trial in the United States on August 9.

12, Zhejiang Pharmaceutical: 2010/0/.6, received a written notice from the US FDA that the on-site inspection report of benflumetol and artemether APIs produced by Xinchang Pharmaceutical Factory under the company has been officially approved by the US FDA and allowed to enter the US market for sale;

13, Changchun High-tech: growth hormone aqua, long-acting growth hormone, oral growth hormone, becoming the world's leading growth hormone production and sales company; Growth hormone will be demonstrated by FDA;

14, Hengrui Pharmaceutical: Repagliptin successfully entered the first phase clinical trial in the United States;

15, Hai: the world's largest manufacturer of heparin sodium raw materials, and the only enterprise in China that has obtained both FDA certification and CEP certification;

16, Luopu Pharmaceutical Co., Ltd.: The product of ofloxacin obtained the COS certificate issued by the European Pharmacopoeia Commission, making Kangyu Pharmaceutical one of the few enterprises in the world to obtain the COS certificate of this product. The project "development of immobilized D- hydantoinase and D- carbamoyl hydrolase" developed by the company was included in the national 863 plan.

Exclusive gene series: 1, Tibet Pharmaceutical: a national first-class new drug, freeze-dried recombinant human brain natriuretic peptide, also known as neoactive, is a gene drug for treating heart failure. So far, only China and the United States have succeeded in research;

2. tonghua dongbao: Recombinant human insulin;

3. Baiyi Pharmaceutical: Soluble Vascular Endothelial Cell Growth Inhibitor (VEGI);

4. Tianmu Pharmaceutical: freeze-dried mouse epidermal growth factor;

5. Haizheng Pharmaceutical: the first gene drug tumor necrosis factor receptor antibody fusion protein entered the phase II clinical trial;

6. Zhongxin Pharmaceutical Co., Ltd.: The world's first "prefilled" recombinant human interferon α-2b injection-Anfulong water injection, and the world's first recombinant human interferon α-2b spray-Fu Jie, filled the domestic gap;

7. Changchun High-tech: growth hormone aqua, long-acting growth hormone and oral growth hormone, becoming the world's leading growth hormone production and sales company; Growth hormone will be demonstrated by FDA;

8. anke biotechnology Science and Technology: the only company that produces interferon and growth hormone at the same time;

9. Daan Gene: The company is a biomedical high-tech enterprise with molecular diagnosis technology as the leading factor, integrating the research and development, production and sales of clinical laboratory reagents and instruments, as well as clinical laboratory services of independent domestic chain medicine laboratories.

Pharmaceutical Business Series: 1, Nanjing Pharmaceutical: the fourth largest pharmaceutical circulation enterprise in China;

2. First medicine: the second largest pharmaceutical circulation enterprise in Shanghai;

3. Sinopharm Holdings: The company is one of the 4 1 national cross-provincial retail chain pilot enterprises and 8 pharmaceutical e-commerce pilot enterprises recognized by the State Administration of Pharmaceutical Products. The controlling shareholder is Sinopharm Holdings (HK1099); );

4. Fosun Pharma: Sinopharm Holdings (HK 1099), which holds 34.66% of the shares, maintains the status of domestic drug distribution 1;

5. China Pharmaceuticals: GmbH ranks 1 among Chinese-funded enterprises in the total import and export of medicines in the health care industry, and ranks third in the whole industry;

6. Tongrentang: There are nearly 500 "Beijing Tongrentang Stores" and nearly 1000 image counters; The Group has also opened 20 branches in 13 countries and regions around the world.

7. Consistent Pharmaceutical: Holding 0/00% equity of Sinopharm Guangzhou Company/KLOC-0. Guangzhou Company is the core enterprise of Sinopharm in South China, with more than 800 pharmaceutical commercial distribution networks covering 29 large and medium-sized cities in various provinces, municipalities and districts across the country;

8. Christie's: the largest pharmaceutical company in Beijing;

9. Jiuzhoutong: the third in the national pharmaceutical industry and the first in the private pharmaceutical industry;

10, Intel Group: wholesale of medicines and medical devices;

165438+

12, Harbin Pharmaceutical Co., Ltd.: "National brand generic drug enterprise+regional business leader", one of the five roses of the company's regional industrial and commercial integration: the industrial chain covers six major pharmaceutical industries, and it is a national brand generic drug company; The pharmaceutical business network is perfect: there are more than 0/000 chain pharmacies/KLOC-0, and the pure sales, wholesale and retail businesses account for about 80%, 66% and 76% of Harbin's share respectively. Is the only commercial company with the province's coverage capacity, and is expected to further expand in Northeast China.

Hospital chain series: 1, Tongce Medical: stomatological hospital chain;

2. Ma Yinglong: anorectal hospital chain;

3. Aier Ophthalmology: Eye Hospital Chain.

Large infusion series:

1, Shuanghe Pharmaceutical

2. Kelun Pharmaceutical

3. Huaren Pharmaceutical

4. tonghua dongbao

Medical equipment series:

1, Wandong Medical: the medical X-ray machine ranks first in China, and China Resources is the controlling shareholder;

2. xinhua medical: Cleaning sterilizers fill the domestic gap, and Purple Mine Group is the controlling shareholder;

3. Yuyue Medical: stethoscope, sphygmomanometer, oxygen generator, wheelchair;

4. Lepu Medical: intravascular drug eluting stent system;

5. Yangpu Medical: the third generation vacuum blood collection system;

6. Xinlitai: high-end medical devices;

7. Hainan Haiyao: cochlear implant;

8. Jiuan Medical: electronic sphygmomanometer, blood glucose meter and low-frequency therapeutic instrument.

Vitamin series: 1, Northeast Pharmaceutical: one of the "five families" of vitamin C and one of the four leading enterprises in China;

2. Huabei Pharmaceutical: one of the largest cephalosporin manufacturers in China, taking into account the manufacture of drugs such as vitamin C;

3. Guangji Pharmaceutical: The company solved the problem of producing vitamin B2 by replacing molasses with rice through revolutionary technological changes, which greatly improved the production efficiency and reduced the cost. The output exceeds 2000 tons, and the leading product is riboflavin.

4. Xinhecheng: The company is a national key high-tech enterprise with high technology, high growth and high efficiency, mainly engaged in the production and sales of drugs, health care products and pharmaceutical raw materials. The production of trimethylhydroquinone and isophytol, the intermediates of vitamin E, ranks first in China. The leading product is vitamin e.

Biochemical pharmaceutical series:

1, Fengyuan Pharmaceutical: biopharmaceuticals, traditional Chinese medicines, chemical synthetic medicines and their preparations and feed additives;

2. Neptune biology: biological products, biochemical products, marine drugs, marine biological products, Chinese patent medicines, etc. ;

3. Livzon Group: bioengineered drugs, raw materials for chemical synthesis, antibiotics, etc.

4. Tetracyclic organisms: recombinant human interleukin-2 injection, the leading product, is a national first-class biological product;

5. Huashen Group: production and sales of bioengineered products, exclusive production and sales of leading products such as Sanqi Shu Tong Capsule and Sanqi Triethanol Saponin. Chengdu Huashen Biotechnology Co., Ltd., a holding subsidiary, is the first monoclonal antibody radioimmuntargeted drug for the treatment of advanced primary liver cancer.

6. Chengzhi shares: life science, bioengineering, Chinese medicine pharmacy, information technology, fine chemical industry;

7. Xiangxue Pharmaceutical: antiviral oral liquid, Banlangen granules;

8. Fuan Pharmaceutical Co., Ltd.: engaged in research and development, production and sales of antibiotic raw materials and preparations. The main products are aztreonam raw materials and preparations, ticarcillin sodium and sulbenicillin sodium raw materials, cefathiamidine and ceftizoxime sodium preparations, among which aztreonam raw materials and preparations are the leading products of the company;

9.R&D Hanyu Pharmaceutical Co., Ltd.: produces and sells chemical synthetic peptides drugs. The main products are peptide pharmaceutical preparations, peptide raw materials and customer peptides (customized services);

10, Xinghu Technology: produces and sells chemical raw materials, nucleoside (acid) and amino acid biochemical products, and its holding subsidiary Anzekang (Beijing) Biotechnology Co., Ltd. implements freeze-dried human rabies vaccine (chicken embryo cells).

1 1, Hualan Bio: The company is a national key high-tech enterprise engaged in the research and development and production of blood products. It passed the GMP certification of the blood products industry for the first time on 1998, and is a national designated large-scale biological product manufacturer, which is in a leading position among domestic enterprises in the same industry.

12. Ke Hua Bio: The company is an in vitro diagnostic reagent manufacturer with the largest output, the highest market share, the most complete variety and the largest batch reported in China.

13, Shutaishen: The company independently developed a national first-class new drug-Sutaisheng, a mouse nerve growth factor for injection, and Shutaiqing, the only bowel-clearing drug with two indications of bowel clearing and constipation in China.